Market Overview

US Stock Futures Rise Ahead Of Economic Data

Share:
US Stock Futures Rise Ahead Of Economic Data

Pre-open movers

US stock futures traded higher in early pre-market trade. The services PMI for September will be released at 9:45 a.m. ET, while the ISM non-manufacturing index for September will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average jumped 83 points to 16,460.0, while the Standard & Poor's 500 index futures rose 10 points to 1,953.00. Futures for the Nasdaq 100 index surged 26.12 points to 4,287.38.

A Peek Into Global Markets

European markets were higher today, with the Spanish Ibex Index gaining 3.16 percent, STOXX Europe 600 Index jumping 2.42 percent and German DAX 30 index gaining 2.23 percent. French CAC 40 Index rose 3.16 percent and London's FTSE 100 Index rose 2.11 percent.

In Asian markets, Japan's Nikkei Stock Average rose 1.58 percent, Hong Kong's Hang Seng Index gained 1.62 percent and India's BSE Sensex climbed 2.15 percent.

Broker Recommendation
Analysts at Goldman Sachs downgraded Viacom, Inc. (NASDAQ: VIAB) from undefined to Neutral and lowered the price target to $46.00.

Viacom shares rose 3.50 percent to close at $44.33 on Friday.

Breaking news

  • Potash Corporation of Saskatchewan (USA) (NYSE: POT) announced that it has withdrawn its proposal to negotiate a transaction with K PLUS S AG ADR (OTC: KPLUY). To read the full news, click here.
  • Mercer, a global consulting leader in advancing health, wealth and careers, and a wholly owned subsidiary of Marsh & McLennan Companies, Inc. (NYSE: MMC), today announced the acquisition of Human Resources Business Solutions (HRBS), a provider of career and talent consulting and information services to clients across Asia, with concentrated strength in Hong Kong, Singapore and mainland China. To read the full news, click here.
  • Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease. To read the full news, click here.
  • Impax Laboratories Inc (NASDAQ: IPXL) today announced that the U.S. Food and Drug Administration (FDA) has approved its generic version of glyburide tablets 1.25 mg, 2.5 mg, and 5 mg. read the full news, click here.

Posted-In: Goldman Sachs US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

 

Related Articles (IPXL + BSX)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

This ETF Is Begging Yellen To Raise Interest Rates

Acorda Therapeutics 8-K Says Co. Agrees With Actavis to Resolve Pending Patent Litigation